Codagenix Inc.
http://www.codagenix.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Codagenix Inc.
Coronavirus Update: Novavax Launches Phase III Trial In UK As Virus Surges Back
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
India’s Draft Guidelines For COVID-19 Vaccines Follow WHO, US Lead
India has rolled out draft guidelines for development of vaccines with special focus on COVID-19 vaccines, drawing from those of other regulatory bodies and the WHO. Experts suggest the primary efficacy endpoint of minimum 50% is acceptable given that vaccines against respiratory diseases are difficult to develop though not necessarily enough to snuff out a pandemic.
Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials
The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.
Novavax-Serum Institute Seal Win-Win Deal For COVID-19 Vaccine
Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools